Epigenetics Market Ultimate Analysis by Leading Players Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Bi

Increasing research to study the epigenetics of the genome (study called epigenomics) is expected to boost growth of the epigenetics market over the forecast period. Genome-wide epigenetic studies play an important role in the diagnostics of human diseases.

Moreover, implementation of epigenetics for oncology research is estimated to propel the growth of epigenetics market. For instance, Constellation Pharmaceuticals, in April 2018, invested US$ 100 million for development of cancer epigenetics platform and ongoing ProSTAR and ORIOn-E trials, which are designed to demonstrate the potential for CPI-1205 and CPI-0610, used for cancer therapy.

PDF Brochure@ https://www.coherentmarketinsights.com/insight/request-pdf/1772

Epigenetics Market – Competitor
1 Illumina
2 Thermo Fisher Scientific
3 Merck Millipore Limited
4 Bio-Rad Laboratories
5 Qiagen Inc
6 Zymo Research Corporation
7 Diagenode s. a
8 Enzo Life Sciences
9 New England Biolabs

Moreover, increasing whole genome sequencing projects such as Human Genome Project is resulting into increasing adoption of epigenetic-based products, which in turn is driving growth of the epigenetics market size.

Increasing government initiatives to enhance epigenetic research is fueling growth of the epigenetics market. For instance, in 2017, National Institutes of Health (NIH) planned to award 10 grants for supporting social epigenomics research in health disparities. The National Institute on Minority Health and Health Disparities (NIMHD), a part of the National Institutes of Health, committed US$ 26.2 million for nine awards over the term of five year.

Moreover, in 2011, epigenetic related research was awarded US$ 11 million grant by the U.S. National Institute of Environmental Health Sciences. In same year, European Commission launched US$ 52.1 million project named BLUEPRINT, which aims to generate 100 reference epigenomes of healthy and leukaemic cells.

Furthermore, organic and inorganic growth strategies such as merger, collaboration, acquisition and product launches by market players of epigenetics market are expected to fuel growth of the epigenetics market.

For instance, in 2012, Epizyme partnered with Summit, a subsidiary of Celgene to develop personalized therapeutics for patients with genetically defined cancers by inhibiting histone methyl transferases (HMTs), an important epigenetic target class. Under this agreement, Celgene will receive an exclusive license outside the U.S. to some of Epizyme’s programs for the period of three years and has the right to extend this option period for one year with additional funding.

Request For Report Sample @ https://www.coherentmarketinsights.com/insight/request-sample/1772

Epigenetics Market Restraint

High maintenance and cost of the instruments such as next generation sequencing or qPCR, implemented for epigenetic study are expected to be the key factors hindering growth of the epigenetics market.

Epigenetics Market Taxonomy

By Product
Consumables
Enzymes
Kits & Reagents
Instruments

By Application
Oncology
Developmental Biology
Drug Development
Metabolic diseases
Other

By End Users
Academic & Research Institutes
Pharmaceuticals & Biopharmaceutical Companies
Contract Research Organizations (CROs)

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1772

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.